The augmentation of eosinophil count (>100/mm3) and of ALC (>1000/mm3) in the circulation after the first infusion of anti-CTLA-4 mAb showed correlation with improved overall survival (OS) in a retrospective analysis of N = 77 metastatic melanoma patients [13]. Here, CTLA4 is linked to metastatic melanoma.